Curis Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

LEXINGTON, Mass., July 29, 2022 /PRNewswire/ — Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that on July 22, 2022, the independent Compensation Committee of the Board of Directors of…

Click here to view original post